Publications

See a complete PubMed list of publications by Sandra Orsulic, PhD.


Selected Key Publications

Orsulic S, Karlan BY. Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy? Gynecol Oncol. 2019 Feb;152(2):221-222. https://www.sciencedirect.com/science/article/pii/S0090825819300058.

Haro M, Orsulic S. A paradoxical correlation of cancer-associated fibroblasts with survival outcomes in B-cell lymphomas and carcinomas. Front Cell Dev Biol. 2018 Aug 28;6:98. https://www.frontiersin.org/articles/10.3389/fcell.2018.00098/full.

Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 2018 Aug 17;8(1):12394. https://www.nature.com/articles/s41598-018-30261-8 .

Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. 2018 Aug;37(35):4809-4820. https://www.nature.com/articles/s41388-018-0297-x.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018 Apr 9;33(4):690-705. https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30119-3.

Watanabe T, Marotta M, Suzuki R, Diede SJ, Tapscott SJ, Niida A, Chen X, Mouakkad L, Kondratova A, Giuliano AE, Orsulic S, Tanaka H. Impediment of replication forks by long non-coding RNA provokes chromosomal rearrangements by error-prone restart. Cell Rep. 2017 Nov 21; 21(8):2223-2235. http://www.cell.com/cell-reports/fulltext/S2211-1247(17)31583-8.

Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett. 2016 Nov 28;382(2):203-214. http://www.cancerletters.info/article/S0304-3835(16)30513-4/fulltext.

Gozo MC, Jia D, Aspuria PJ, Cheon DJ, Miura N, Walts AE, Karlan BY, Orsulic S. FOXC2 augments tumor propagation and metastasis in osteosarcoma. Oncotarget. 2016 Oct 18;7(42):68792-68802. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=11990&path%5B%5D=37946.

Beach JA, Aspuria PJ, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, Karlan BY, Orsulic S. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer. Oncotarget. 2016 Jan 26;7(4):4167-4182. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=6703.

Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, Orsulic S. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol. 2015 Dec;139(3):394-400. http://www.gynecologiconcology-online.net/article/S0090-8258(15)30117-7/fulltext.

Walts AE, Bomalaski JS, Ines D, Orsulic S. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol. 2015 Aug;141(8):1363-1369. http://link.springer.com/article/10.1007%2Fs00432-014-1904-z.

Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, Karlan BY, Orsulic S. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis. 2015 Jul;36(7):739-747. https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgv059.

Aspuria PJ, Lunt SY, Väremo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, Karlan BY, Orsulic S. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2014 Dec 15;2:21. http://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-2-21.

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S. Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res. 2014 Nov 5;1(1):41-53. http://onlinelibrary.wiley.com/doi/10.1002/cjp2.4/full.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014 Feb 1;20(3):711-723. http://clincancerres.aacrjournals.org/content/20/3/711.



Time Warner Cable TV Interview on Local Edition with Brad Pomerance. Spring 2014.